Several biomarkers of CSCs in prostate and other types of cancers have been shown, including CD133/PROM1 [54–56], CD326/EpCAM [56], a chemokine receptor CXCR4 [55, 57], aldehyde dehydrogenase (ALDH) activity [58], Integrin α2 and β1 [54], stimulus-independent PTEN/Akt/PI3K signaling [59], protein fucosylation [60] and CD44 alternative splicing variants (CD44v) [61, 62]. This evidence concerns the gene PROM1 and cancer.